Recombinant Human LILRB1/CD85j/ILT2 Fc Biotin Protein, CF

When Human LILRB1/CD85j/ILT2 Antibody (MAB20172) is immobilized at 0.2 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera Protein (Catalog # BT2017) binds with an ED50 of 1.50-18.0 ng/mL.

2 μg/lane of Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera Biotinylated Protein (Catalog # BT2017) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 93-107 kDa and 190-210 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRB1/CD85j/ILT2 Fc Biotin Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Human LILRB1/CD85j/ILT2 Antibody (Catalog # MAB20172) is immobilized at 0.2 µg/mL (100 µL/well), Biotinylated Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera (Catalog # BT2017) binds with an ED₅₀ of 1.50-18.0 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human LILRB1/CD85j/ILT2 protein
  

  Human LILRB1/CD85j/ILT2 (Gly24-His458) Accession # Q8NHL6.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q8NHL6.1
• N-terminal Sequence: Gly24
• Structure / Form: Disulfide-linked homodimer
  Biotinylated via amines
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 74 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 93-107 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRB1/CD85j/ILT2 Fc Biotin Protein, CF

• CD85 antigen-like family member J
• CD85j antigen
• CD85j
• Ig-like transcript 2
• ILT2
• ILT-2
• ILT2FLJ37515
• Immunoglobulin-like transcript 2
• leukocyte Ig-like receptor-1
• Leukocyte immunoglobulin-like receptor 1
• leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform
• leukocyte immunoglobulin-like receptor subfamily B member 1
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB1
• LIR1
• LIR1LIR-1MIR-7CD85MIR7CD85 antigen
• member 1
• MIR7
• Monocyte/macrophage immunoglobulin-like receptor 7

Background

LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family (1). Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs (2). Alternative splicing generates an additional isoform that lacks the transmembrane and cytoplasmic regions (3). LILRB1 is expressed on the surface of B cells and monocytes, as well as subsets of NK cells, memory/effector CD8+ T cells, gamma δ T cells, and monocyte-derived dendritic cells (3-7). LILRB1 binds to MHC-I as well as non-classical MHC-I molecules (e.g. HLA-F, HLA-G, and HC-B27) and the MHC-I mimetic UL18 encoded by cytomegalovirus (3, 5, 8-10). R&D Systems in-house testing indicates that LILRB1 also binds to Angiopoietin-like 7. Ligation of LILRB1 inhibits the antigen induced proliferation and activation of CD8+ T cells, CD4+ T cells, NK cells, and gamma δ T cells (3, 4, 11-13). On dendritic cells, ligation inhibits the production of IL-10, IL-12p70, and TGF-beta and protects from Fas-mediated apoptosis (7).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Samaridis, J. and M. Colonna (1997) Eur. J. Immunol. 27:660.
3. Colonna, M. et al. (1997) J. Exp. Med. 186:1809.
4. Harly, C. et al. (2011) Blood 117:2864.
5. Cosman, D. et al. (1997) Immunity 7:273.
6. Young, N.T. et al. (2001) J. Immunol. 166:3933.
7. Young, N.T. et al. (2008) Blood 111:3090.
8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
9. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:8856.
10. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
11. Ince, M.N. et al. (2004) Immunology 112:531.
12. Saverino, D. et al. (2000) J. Immunol. 165:3742.
13. Saverino, D. et al. (2002) J. Immunol. 168:207.

Bioinformatics

• Uniprot:
  • Q8NHL6.1()